V
27.00
0.41 (1.54%)
| Previous Close | 26.59 |
| Open | 26.72 |
| Volume | 1,725,382 |
| Avg. Volume (3M) | 3,863,104 |
| Market Cap | 3,032,369,920 |
| Price / Book | 3.46 |
| 52 Weeks Range | |
| Earnings Date | 22 Jul 2025 - 28 Jul 2025 |
| Diluted EPS (TTM) | -1.16 |
| Total Debt/Equity (MRQ) | 0.12% |
| Current Ratio (MRQ) | 44.25 |
| Operating Cash Flow (TTM) | -133.99 M |
| Levered Free Cash Flow (TTM) | -98.38 M |
| Return on Assets (TTM) | -11.74% |
| Return on Equity (TTM) | -14.40% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Viking Therapeutics, Inc. | Bullish | Bearish |
AIStockmoo Score
2.1
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 4.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -2.0 |
| Average | 2.13 |
|
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 2.12% |
| % Held by Institutions | 70.04% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 104.00 (Cantor Fitzgerald, 285.19%) | Buy |
| Median | 102.00 (277.78%) | |
| Low | 30.00 (Goldman Sachs, 11.11%) | Hold |
| Average | 82.60 (205.93%) | |
| Total | 4 Buy, 1 Hold | |
| Avg. Price @ Call | 24.64 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 28 Apr 2025 | 104.00 (285.19%) | Buy | 25.94 |
| Truist Securities | 28 Apr 2025 | 75.00 (177.78%) | Buy | 25.94 |
| HC Wainwright & Co. | 24 Apr 2025 | 102.00 (277.78%) | Buy | 25.66 |
| 17 Apr 2025 | 102.00 (277.78%) | Buy | 23.94 | |
| Morgan Stanley | 24 Apr 2025 | 102.00 (277.78%) | Buy | 25.66 |
| Goldman Sachs | 08 Apr 2025 | 30.00 (11.11%) | Hold | 19.98 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 28 May 2025 | Announcement | Viking Therapeutics to Participate at Upcoming Investor Conferences |
| 23 Apr 2025 | Announcement | Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update |
| 17 Apr 2025 | CNBC | Eli Lilly’s weight loss pill succeeds in first late-stage trial on diabetes patients; shares jump 14% |
| 16 Apr 2025 | Announcement | Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025 |
| 26 Mar 2025 | Announcement | Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity |
| 24 Mar 2025 | CNBC | Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |